Shaoyan et al. found that the mRNA expression of eIF4A2 was increased in 87.6% (148/170) of patients with nonsmall-cell lung carcinoma (NSCLC), and they observed elevated levels of eIF4A2 in tumor tissues (45.29%; 77/170) using immunohistochemistry (Shaoyan et al., 2013b). This evidence concerns the gene EIF4A2 and non-small cell lung carcinoma.